Business

DuPont Launches DuPont™ AmberChrom™ XT SL Chromatography Resins to Simplify Biopharmaceutical Workflows

DuPont (NYSE:DD) today announced the launch of DuPont™ AmberChrom™ XT20 SL and XT30 SL chromatography resins, expanding its bioprocessing portfolio to help manufacturers streamline purification operations for oligonucleotide and peptide therapeutics.

articleDupont De Nemours, Inc.April 14, 20263/company/dupont-de-nemours-inc/news/dupont-launches-duponttm-amberchromtm-xt-sl-chromatography-resins-to-simplify-biopharmaceutical-workflows
DuPont Launches DuPont™ AmberChrom™ XT SL Chromatography Resins to Simplify Biopharmaceutical Workflows

About this update from Dupont De Nemours, Inc.

[{"type":"text","content":"New slurried chromatography resins eliminate resin hydration step to help accelerate downstream purification of oligonucleotides and peptides","length":141,"tagName":"p"},{"type":"text","content":"WILMINGTON, Del., April 14, 2026 /PRNewswire/ -- DuPont (NYSE:DD) today announced the launch of DuPont™ AmberChrom™ XT20 SL and XT30 SL chromatography resins, expanding its bioprocessing portfolio to help manufacturers streamline purification operations for oligonucleotide and peptide therapeutics.","length":299,"tagName":"p"},{"type":"image","alt":"DuPont Logo (PRNewsfoto/DuPont)","displaySize":"","headline":null,"caption":"DuPont Logo (PRNewsfoto/DuPont)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":116,"url":"https://media.zenfs.com/en/prnewswire.com/2afc4d09101aeb9068e83f4cbae39368"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6PSAdlfFo8qBZlzgYmrYOg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIwNA--/https://media.zenfs.com/en/prnewswire.com/2afc4d09101aeb9068e83f4cbae39368","width":400,"height":116}},"href":"https://mma.prnewswire.com/media/1167395/dupont_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Oligonucleotide and peptide therapeutics are a growing class of targeted medicines used to treat a range of diseases—particularly genetics and rare disorders, metabolic conditions (such as diabetes and obesity), and some cancers—by precisely modulating specific biologic pathways. These therapeutics require specialized purification solutions to achieve the purity and consistency needed for clinical and commercial production. As development pipelines expand, manufacturers are increasingly focused on improving efficiency in downstream processing to support consistent quality and scalable production.","length":603,"tagName":"p"},{"type":"text","content":"The newly introduced DuPont™ AmberChrom™ XT20 SL and XT30 SL chromatography resins are slurried versions of the company's existing DuPont™ AmberChrom™ XT resins and are designed to simplify downstream workflows by eliminating the need for resin hydration prior to column packing. The column packing stage can require significant capital investment, including specialized equipment and additional resources, making preparation steps a key operational challenge for manufacturers. By enabling manufacturers to move directly fr...

More updates from Dupont De Nemours, Inc.

peptide therapeuticsDuPontXT20 SLdownstream processingSLmanufacturers